Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Tells Response Genetics it May Face Delisting of Shares

NEW YORK (GenomeWeb) – Response Genetics said on Tuesday that it has been notified by the Nasdaq that it is not in compliance with a requirement to continue listing its shares on the exchange.

In a document filed with the US Securities and Exchange Commission, the Los Angeles-based molecular diagnostics company said it received a letter on June 20 from the Nasdaq staff stating that for the previous 30 consecutive business days, its shares had closed below the minimum $1 per share bid price for continued listing on the Nasdaq Capital Market.

Response Genetics has 180 days, or until Dec. 17, to regain compliance by lifting the bid price to at least $1 per share for 10 consecutive business days before the deadline. If it fails to do so, the company may be given an additional 180 days to regain compliance if it meets other listing requirements, excepting the $1 minimum bid price condition. The firm would also need to provide written notice to Nasdaq that it intends to meet the bid price requirement by carrying out a reverse stock split, if necessary.

Nasdaq may move to delist Response Genetics' shares if it believes the company will not be able to meet all listing conditions. Response Genetics said in its SEC document that it will monitor the stock's bid price and its minimum market value "and will consider options available to it to achieve compliance."

In morning trading on Wednesday, the company's shares were up about 2 percent to $1.03.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.